Back

Pharmacological selectivity of SGLT2 inhibitors and cardiovascular outcomes in patients with type 2 diabetes: a meta-analysis

27 August 2022 (13:15 - 13:55)
Organised by:
Congress Presentation Part of: SGLT2 inhibitors in clinical practice Antidiabetic Pharmacotherapy ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Alex Ali Sayour

Semmelweis University Heart and Vascular Center, Budapest (Hungary)

6 More presentations in this session

Presentation thumbnail
Absolute treatment effects of novel oral antidiabetic drugs on cardiovascular mortality and hospitalization for heart failure: a meta-analysis of digitalized individual patient outcomes
Mr G. Wolff (Ibbenbüren, DE)
Abstract Slides
Presentation thumbnail
The gender gap in prescription pattern of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes
Mr A. Hammer (Vienna, AT)
Abstract Slides
Presentation thumbnail
Impact of SGLT2 inhibitor on mortality and cardiovascular outcomes in patients with type 2 diabetes mellitus with left main or multivessel coronary artery disease
Doctor D. Chipayo Gonzales (Caceres, ES)
Abstract Slides
Presentation thumbnail
Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes patients: a propensity score-matched study
Mr O. Chou (Hong Kong, HK)
Abstract Slides
Presentation thumbnail
Characterization of the SGLT2 interaction network and its regulation by SGLT2 inhibitors: a bioinformatic analysis
Miss A. Nowak (Warsaw, PL)
Abstract Slides

Access the full session

Session thumbnail
SGLT2 inhibitors in clinical practice

The Event

Event poster

ESC Congress 2022

27 August 2022 13:15 CET
You may be interested in
thumbnail
Congress Session
Guidelines in Practice: 2023 ESC Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes
thumbnail
Congress Presentation
Antithrombotic therapy in diabetes
thumbnail
Congress Session
2023 ESC Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources